Lauren Hartle
Analista di Private Equity presso Prime Impact Fund
Profilo
Lauren Hartle is currently an Associate at Prime Impact Fund since 2020.
Previously, she worked as a Development Technician at AlphaVax, Inc. from 2008 to 2009.
Dr. Hartle holds a doctorate degree from Harvard University and an undergraduate degree from the University of North Carolina System, which she received in 2007.
Posizioni attive di Lauren Hartle
| Società | Posizione | Inizio |
|---|---|---|
Prime Impact Fund
 Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Analista di Private Equity | 01/06/2020 |
Precedenti posizioni note di Lauren Hartle
| Società | Posizione | Fine |
|---|---|---|
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/06/2009 |
Formazione di Lauren Hartle
| Harvard University | Doctorate Degree |
| University of North Carolina System | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Prime Impact Fund
Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Lauren Hartle
